INM
InMed Pharmaceuticals Inc.
1.58
1 x 1.15
2 x 2.03
bid
ask
-
0.01
0.31%
10:15 AM
timesize
| Ytd | 49.53% | |
| 1y | -48.03% |
1.57
day range
1.59
0.57
52 week range
3.28
| Open | 1.58 | Prev Close | 1.59 | Low | 1.57 | High | 1.59 | Mkt Cap | 5.25M |
| Vol | 5.71K | Avg Vol | 1.68M | EPS | -1.47 | P/E | N/A | Forward P/E | -0.75 |
| Beta | 0.71 | Short Ratio | 0.12 | Inst. Own | 8.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 1.22 | 200-d Avg | 1.30 | 1yr Est | 20.00 |
| Income Statement | |||
| Operating Expenses | 2.82M | ||
| Research and Development Expense | 1.02M | ||
| Selling, General and Administrative Expense | 1.74M | ||
| Operating Income | -2.82M | ||
| Net Income | -2.97M | ||
| Net Income Common Stock | -2.97M | ||
| Net Income Common Stock (USD) | -2.97M | ||
| Consolidated Income | -2.97M | ||
| Net Income from Discontinued Operations | 174.59K | ||
| Earnings per Basic Share | -0.73 | ||
| Earnings per Basic Share (USD) | -0.73 | ||
| Earnings per Diluted Share | -0.73 | ||
| Earning Before Interest & Taxes (EBIT) | -2.97M | ||
| Earning Before Interest & Taxes (USD) | -2.97M | ||
| Weighted Average Shares | 4.05M | ||
| Weighted Average Shares Diluted | 4.05M | ||
| Balance Sheet | |||
| Cash and Equivalents | 5.16M | ||
| Cash and Equivalents (USD) | 5.16M | ||
| Investments | 41.63K | ||
| Investments Current | 41.63K | ||
| Current Assets | 6.89M | ||
| Property, Plant & Equipment Net | 642.88K | ||
| Total Assets | 9.13M | ||
| Debt Current | 389.38K | ||
| Total Debt | 389.38K | ||
| Current Liabilities | 2.21M | ||
| Total Liabilities | 2.24M | ||
| Accumulated Retained Earnings (Deficit) | -123.96M | ||
| Accumulated Other Comprehensive Income | 128.57K | ||
| Shareholders Equity | 6.89M | ||
| Shareholders Equity (USD) | 6.89M | ||
| Assets Non-Current | 2.25M | ||
| Total Debt (USD) | 389.38K | ||
| Goodwill and Intangible Assets | 1.50M | ||
| Liabilities Non-Current | 30.77K | ||
| Trade and Non-Trade Payables | 1.01M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 133.46K | ||
| Net Cash Flow from Financing | 231.68K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -1.46M | ||
| Issuance (Purchase) of Equity Shares | 231.68K | ||
| Net Cash Flow from Operations | -1.70M | ||
| Share Based Compensation | 38.77K | ||